fda approval semaglutide Oral Wegovy approved for obesity management by on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Wegovy as a Pill Is

Semaglutide medication tells your body to release insulin, so your blood sugar may drop lower than usual, causing sluggishness or fatigue

Whats substantial reductions in body weight to researchers simply becomes wow, my life back to people who live with obesity

4% (placebo) due to adverse events Clinical Significance: This pivotal Phase 2 study established cagrilintide as an effective monotherapy for obesity, producing weight loss competitive with GLP-1 agonists but through a distinct mechanism

At 0.25mg per week, a single 5mg vial lasts 20 weeks

People who may benefit from resM Those who do not qualify for prescription GLP-1 medications